Avanir Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avanir Pharmaceuticals, Inc.
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.
The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.
- Other Names / Subsidiaries
- Alamo Pharmaceuticals, LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.